Literature DB >> 29542810

Inflammasome Activation Characterizes Lesional Skin of Folliculitis Decalvans.

Alexia Eyraud1, Brigitte Milpied, Denis Thiolat, Anne-Sophie Darrigade, Katia Boniface, Alain Taïeb, Julien Seneschal.   

Abstract

Folliculitis decalvans (FD) is a chronic inflammatory disease leading to scarring alopecia with poorly defined pathogenesis. The aim of this study was to investigate the expression of markers associated with the activation of innate immune signals, such as inflammasome (NALP1 and NALP3), interleukin (IL)-1β and IL-8 and type I interferon (MxA). A retrospective monocentric study was conducted and included 17 patients with FD with available biopsies. Disease activity (stable vs. active) was defined clinically and histologically. Immunostaining was performed using antibodies directed against NALP1, NALP3, IL-1β, IL-8, and MxA on FD skin biopsies. Results were compared with normal controls and lichen planopilaris. Eleven patients had active disease and 6 had stable disease. NALP1, NALP3, and IL-1β expression were significantly increased in hair follicles in FD compared with controls and lichen planopilaris. This study highlights the predominant immune signal associated with inflammasome activation in FD, suggesting the use of IL-1β blockade in FD.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29542810     DOI: 10.2340/00015555-2924

Source DB:  PubMed          Journal:  Acta Derm Venereol        ISSN: 0001-5555            Impact factor:   4.437


  2 in total

1.  Reflectance Confocal Microscopy Applied to Folliculitis Decalvans: Preliminary Results of a Multicenter Study.

Authors:  Sara Mazzilli; Laura Vollono; Francesco Tassone; Simone Cappilli; Ketty Peris; Luca Bianchi
Journal:  Skin Appendage Disord       Date:  2020-06-03

2.  The role of NLRP1 and NLRP3 inflammasomes in the etiopathogeneses of pityriasis lichenoides chronica and mycosis fungoides: an immunohistochemical study.

Authors:  Ecem Bostan; Ozay Gokoz; Nilgun Atakan
Journal:  Arch Dermatol Res       Date:  2022-07-01       Impact factor: 3.017

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.